Gut dysbiosis impairs intestinal renewal and lipid absorption in Scarb2 deficiency-associated neurodegeneration
Received date: 22 Oct 2023
Accepted date: 05 Mar 2024
Copyright
Scavenger receptor class B, member 2 (SCARB2) is linked to Gaucher disease and Parkinson’s disease. Deficiency in the SCARB2 gene causes progressive myoclonus epilepsy (PME), a rare group of inherited neurodegenerative diseases characterized by myoclonus. We found that Scarb2 deficiency in mice leads to age-dependent dietary lipid malabsorption, accompanied with vitamin E deficiency. Our investigation revealed that Scarb2 deficiency is associated with gut dysbiosis and an altered bile acid pool, leading to hyperactivation of FXR in intestine. Hyperactivation of FXR impairs epithelium renewal and lipid absorption. Patients with SCARB2 mutations have a severe reduction in their vitamin E levels and cannot absorb dietary vitamin E. Finally, inhibiting FXR or supplementing vitamin E ameliorates the neuromotor impairment and neuropathy in Scarb2 knockout mice. These data indicate that gastrointestinal dysfunction is associated with SCARB2 deficiency-related neurodegeneration, and SCARB2-associated neurodegeneration can be improved by addressing the nutrition deficits and gastrointestinal issues.
Key words： gut dysbiosis; intestinal renewal; neuron disease
Yinghui Li , Xingchen Liu , Xue Sun , Hui Li , Shige Wang , Wotu Tian , Chen Xiang , Xuyuan Zhang , Jiajia Zheng , Haifang Wang , Liguo Zhang , Li Cao , Catherine C.L. Wong , Zhihua Liu . Gut dysbiosis impairs intestinal renewal and lipid absorption in Scarb2 deficiency-associated neurodegeneration[J]. Protein & Cell, : 1 -22 . DOI: 10.1093/procel/pwae016
| 1 |
Ahmadi S, Wang S, Nagpal R et al. A human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation via modulating the microbiota/taurine/tight junction axis. JCI insight 2020;5:e132055.
|
| 2 |
Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson’s disease. Movement Disord 2009;24:1881–1892.
|
| 3 |
Blauwendraat C, Heilbron K, Vallerga CL et al. 23andMe Research Team. Parkinson’s disease age at onset genome-wide association study: defining heritability, genetic loci, and α-synuclein mechanisms. Movement 2019;34:866–875.
|
| 4 |
Calvo D, Dopazo J, Vega MA. The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution. Genomics 1995;25:100–106.
|
| 5 |
Choi SB, Lew LC, Yeo SK et al. Probiotics and the BSH-related cholesterol lowering mechanism: a Jekyll and Hyde scenario. Crit Rev Biotechnol 2015;35:392–401.
|
| 6 |
Clifford BL, Sedgeman LR, Williams KJ et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab 2021;33:1671–1684. e4.e4.
|
| 7 |
Collins SL, Stine JG, Bisanz JE et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol 2023;21:236–247.
|
| 8 |
de Aguiar Vallim TQ, Tarling EJ, Ahn H et al. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab 2015;21:298–311.
|
| 9 |
Dossa AY, Escobar O, Golden J et al. Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling. Am J Physiol Gastrointest Liver Physiol 2016;310:G81–G92.
|
| 10 |
Fang S, Suh JM, Reilly SM et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21:159–165.
|
| 11 |
Fu T, Coulter S, Yoshihara E et al. FXR regulates intestinal cancer stem cell proliferation. Cell 2019;176:1098–1112. e18.e18.
|
| 12 |
He M, Tang BS, Li N et al. Using a combination of whole-exome sequencing and homozygosity mapping to identify a novel mutation of SCARB2. Clin Genet 2014;86:598–600.
|
| 13 |
Hill DA, Hoffmann C, Abt MC et al. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol 2010;3:148–158.
|
| 14 |
Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217–225.
|
| 15 |
Jiang C, Xie C, Li F et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015a;125:386–402.
|
| 16 |
Jiang C, Xie C, Lv Y et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015b;6:10166.
|
| 17 |
Jin L, Feng X, Rong H et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 2013;4:1937.
|
| 18 |
Kałużna M, Trzeciak I, Ziemnicka K et al. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet J Rare Dis 2019;14:275.
|
| 19 |
Kamphorst JJ, Fan J, Lu W et al. Liquid chromatography-high resolution mass spectrometry analysis of fatty acid metabolism. Anal Chem 2011;83:9114–9122.
|
| 20 |
Kerr TA, Saeki S, Schneider M et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell 2002;2:713–720.
|
| 21 |
Kim J, Kim H, Noh SH et al. Grasp55−/− mice display impaired fat absorption and resistance to high-fat diet-induced obesity. Nat Commun 2020;11:1418.
|
| 22 |
Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15/19 Pathway. Dig Dis 2015;33:327–331.
|
| 23 |
Koliaraki V, Pasparakis M, Kollias G. IKKβin intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med 2015;212:2235–2251.
|
| 24 |
Krndija D, El Marjou F, Guirao B et al. Active cell migration is critical for steady-state epithelial turnover in the gut. Science (New York, N.Y.) 2019;365:705–710.
|
| 25 |
Li F, Jiang C, Krausz KW et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013;4:2384.
|
| 26 |
Li Z, Liang H, Hu Y et al. Gut bacterial profiles in Parkinson’s disease: a systematic review. CNS Neurosci Therap 2023;29:140–157.
|
| 27 |
Marizzoni M, Provasi S, Cattaneo A et al. Microbiota and neurodegenerative diseases. Curr Opin Neurol 2017;30:630–638.
|
| 28 |
Mazzulli JR, Xu YH, Sun Y et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37–52.
|
| 29 |
Michelakakis H, Xiromerisiou G, Dardiotis E et al. Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson’s disease. Movement Disord 2012;27:400–405.
|
| 30 |
Mina AI, LeClair RA, LeClair KB et al. CalR: a web-based analysis tool for indirect calorimetry experiments. Cell Metab 2018;28:656–666.e1.e1.
|
| 31 |
Reczek D, Schwake M, Schröder J et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007;131:770–783.
|
| 32 |
Romano S, Savva GM, Bedarf JR et al. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinson’s Dis 2021;7:27.
|
| 33 |
Rothaug M, Zunke F, Mazzulli JR et al. LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. Proc Natl Acad Sci USA 2014;111:15573–15578.
|
| 34 |
Santander N, Lizama C, Parga MJ et al. Deficient vitamin E uptake during development impairs neural tube closure in mice lacking lipoprotein receptor SR-BI. Sci Rep 2017;7:5182.
|
| 35 |
Sayin SI, Wahlström A, Felin J et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17:225–235.
|
| 36 |
Schirinzi T, Martella G, Imbriani P et al. Dietary vitamin E as a protective factor for Parkinson’s disease: clinical and experimental evidence. Front Neurol 2019;10:148.
|
| 37 |
Seok S, Kim YC, Zhang Y et al. Feeding activates FGF15-SHP-TFEB-mediated lipophagy in the gut. EMBO J 2022;41:e109997.
|
| 38 |
Sokol RJ, Heubi JE, Iannaccone S et al. Mechanism causing vitamin E deficiency during chronic childhood cholesta-sis. Gastroenterology 1983;85:1172–1182.
|
| 39 |
Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. The J Neurosci 2009;29:13589–13602.
|
| 40 |
Tanaka H, Doesburg K, Iwasaki T et al. Screening of lactic acid bacteria for bile salt hydrolase activity. J Dairy Sci 1999;82:2530–2535.
|
| 41 |
Tian WT, Liu XL, Xu YQ et al. Progressive myoclonus epilepsy without renal failure in a Chinese family with a novel mutation in SCARB2 gene and literature review. Seizure 2018;57:80–86.
|
| 42 |
Urso D, van Wamelen DJ, Batzu L et al. Clinical trajectories and biomarkers for weight variability in early Parkinson’s disease. NPJ Parkinsons Dis 2022;8:95.
|
| 43 |
van Tilborg E, van Kammen CM, de Theije CGM et al. A quantitative method for microstructural analysis of myelinated axons in the injured rodent brain. Sci Rep 2017;7:16492.
|
| 44 |
van Zutphen T, Bertolini A, de Vries HD et al. Potential of intestine-selective FXR modulation for treatment of metabolic disease. Handb Exp Pharmacol 2019;256:207–234.
|
| 45 |
Velayati A, DePaolo J, Gupta N et al. A mutation in SCARB2 is a modifier in Gaucher disease. Hum Mutat 2011;32:1232–1238.
|
| 46 |
Wahlström A, Sayin SI, Marschall HU et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 2016;24:41–50.
|
| 47 |
Wang L, Lee YK, Bundman D et al. Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2002;2:721–731.
|
| 48 |
Warnecke T, Schäfer KH, Claus I et al. Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management. NPJ Parkinson’s Dis 2022;8:31.
|
| 49 |
Wills AM, Li R, Pérez A et al. Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort. J Neurol 2017;264:1746–1753.
|
| 50 |
Yokota T, Igarashi K, Uchihara T et al. Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc Natl Acad Sci USA 2001;98:15185–15190.
|
| 51 |
Yoo D, Lim Y, Son Y et al. Dietary intake and plasma levels of polyunsaturated fatty acids in early-stage Parkinson’s disease. Sci Rep 2021;11:12489.
|
| 52 |
Zhang Q, Pan Y, Yan R et al. Commensal bacteria direct selective cargo sorting to promote symbiosis. Nat Immunol 2015;16:918–926.
|
| 53 |
Zhao Q, Wu J, Ding Y et al. Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions. Life Metab 2023;2:1–19.
|
| 54 |
Zhu JW, Li YF, Wang ZT et al. Toll-like receptor 4 deficiency impairs motor coordination. Front Neurosci 2016;10:33.
|
| 55 |
Zou Y, Pei J, Wang Y et al. The deficiency of SCARB2/LIMP-2 impairs metabolism via disrupted mTORC1-dependent mitochondrial OXPHOS. Int J Mol Sci 2022;23:8634.
|
/
| 〈 |
|
〉 |